BioTime, Jade sign sublicense agreement for HyStem technology
According to the agreement, BioTime will provide Jade with clinical-grade HyStem hydrogels and certain patented technology for use in the development of new pharmaceutical products for ophthalmologic use.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.